Zai Lab (NASDAQ:ZLAB) Lowered to “Hold” at Zacks Investment Research


Share on StockTwits

Zacks Investment Research downgraded shares of Zai Lab (NASDAQ:ZLAB) from a buy rating to a hold rating in a report released on Wednesday morning, Zacks.com reports.

According to Zacks, “Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company’s product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China. “

Separately, JPMorgan Chase & Co. increased their price target on Zai Lab from $101.00 to $111.00 in a report on Monday, November 16th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Zai Lab presently has an average rating of Buy and an average target price of $100.00.

Shares of NASDAQ ZLAB traded up $7.21 during mid-day trading on Wednesday, hitting $160.86. 4,830 shares of the company were exchanged, compared to its average volume of 338,328. The stock has a 50 day simple moving average of $123.26 and a 200-day simple moving average of $93.95. Zai Lab has a 1-year low of $43.06 and a 1-year high of $156.60. The firm has a market cap of $9.35 billion, a price-to-earnings ratio of -50.71 and a beta of 0.95.

Large investors have recently made changes to their positions in the stock. US Bancorp DE lifted its position in Zai Lab by 111.9% in the third quarter. US Bancorp DE now owns 1,714 shares of the company’s stock valued at $142,000 after purchasing an additional 905 shares during the period. DekaBank Deutsche Girozentrale lifted its position in Zai Lab by 381.8% in the third quarter. DekaBank Deutsche Girozentrale now owns 17,432 shares of the company’s stock valued at $1,421,000 after purchasing an additional 13,814 shares during the period. Point72 Asset Management L.P. acquired a new stake in Zai Lab in the second quarter valued at about $90,000. Swiss National Bank lifted its position in Zai Lab by 37.0% in the third quarter. Swiss National Bank now owns 136,871 shares of the company’s stock valued at $11,384,000 after purchasing an additional 36,966 shares during the period. Finally, Great West Life Assurance Co. Can lifted its position in Zai Lab by 25.3% in the second quarter. Great West Life Assurance Co. Can now owns 38,182 shares of the company’s stock valued at $3,130,000 after purchasing an additional 7,700 shares during the period. Hedge funds and other institutional investors own 81.32% of the company’s stock.

About Zai Lab

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, autoimmune, and infectious diseases in China. The company offers Niraparib, an oral small molecule poly ADP ribose polymerase 1/2 inhibitor for the treatment of multiple solid tumors, including ovarian and other types of lung cancer; and Optune, a cancer therapy for the treatment of glioblastoma multiforme.

Read More: What is a recession?

Get a free copy of the Zacks research report on Zai Lab (ZLAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.